PAR 1.79% 27.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-543

  1. 572 Posts.
    lightbulb Created with Sketch. 55
    why do you think its a PAR study? There are other manufacturers of PPS, and this study wont have to use PARs supplier. also, may be wrong but it aopears its targeting a different mechanism which doesnt infringe on the BMEL patents. smart.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.